Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

First-in-human, Phase I clinical trial holds great promise for the development of an effective vaccine against genital chlamydia

Recently, a first-in-human, Phase I clinical trial was successfully completed for a novel chlamydia vaccine. The trial results hold great promise for the development of an effective vaccine against genital chlamydia, says GlobalData, a leading data and analytics company. The trial aimed to evaluate both the safety and efficiency of the vaccine, with the latter […]
Read more

Healthcare professionals say the UK WILL NOT leave the EU on the current withdrawal agreement on 31 October in latest GlobalData survey

Healthcare industry professionals around the world believe that Brexit will not happen on the current withdrawal agreement on 31 October, but there will also be no cancellation of Brexit, the latest survey data from GlobalData, a leading data and analytics company, suggests. GlobalData’s latest report, ‘Brexit and the Healthcare Industry – Implications for Pharma, Q2 […]
Read more

Manipulated Zolgensma data may add to further woes for Novartis

Zolgensma’s recent challenge of finding favor with the majority of the insurance companies in the US may just be about to get tougher with the news on manipulation in pre-clinical data. Vinie Varkey, Senior Analyst of Neurology & Ophthalmology at GlobalData, a leading data and analytics company, offers her view on what this means for […]
Read more

Precision medicine set to make steady headway in Japan, says GlobalData

Japan has recently become the first country to approve Roche/Chugai’s personalized medicine Rozlytrek (entrectinib) for adult and pediatric patients with neurotrophic tyrosine receptor kinase (NTRK) fusion-positive advanced recurrent solid tumors. Against this back drop, precision medicine is set to make steady headway in Japan, says GlobalData, a leading data and analytics company. Sasmitha Sahu, Pharma […]
Read more

Despite resubmission of Viaskin Peanut BLA, AR-101’s likely first-to-market advantage could still setback DBV Technologies

Following the news that DBV Technologies has submitted a biologics license application (BLA) to the US FDA for Viaskin Peanut, an epicutaneous immunotherapy for the treatment of peanut allergy, Rose Joachim, PhD, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “Although DBV’s recent BLA resubmission for Viaskin Peanut has […]
Read more

Almost 70% of CMO high-containment facilities in Europe can be found in the 5EU and Switzerland

Approximately 69% of contract manufacturing organization (CMO) high-containment facilities in Europe can be found in the five major European markets (5EU*) and Switzerland, according to GlobalData, a leading data and analytics company. GlobalData’s latest research reveals that the European contract manufacturing industry has invested heavily in containment capabilities. Adam Bradbury, PharmSource Analyst at GlobalData, comments: […]
Read more

South Korea’s pharma-biotech space to attract foreign investment as market set to be worth US$23.2bn by 2022, says GlobalData

South Korea’s plans to invest more than US$1.7bn in its biotechnology and biopharmaceutical sectors over the next five years will attract foreign investment as pharmaceutical market growth is set to increase from nearly US$19.5bn in 2018 to more than US$23.2bn by 2022, says GlobalData, a leading data and analytics company. Prashant Khadayate, Pharma Analyst at […]
Read more

Lupus pipeline sees high levels of innovation with 43% first-in-class, says GlobalData

The systemic lupus erythematosus (SLE) pipeline is characterized by a high level of first-in-class innovation when compared to other therapy areas and the industry as a whole, says GlobalData, a leading data and analytics company.  GlobalData’s recent report, ‘Systemic Lupus Erythematosus: Programs Targeting Cytokine and Growth Factor Signaling Dominate First-in-Class Pipeline’, reveals that the high […]
Read more

Bayer and Orion’s Nubeqa could gain regulatory approval in EU and Japan next year despite being late-to-market for prostate cancer

Following the news that Bayer and Orion’s Nubeqa (darolutamide) has gained US Food and Drug Administration (FDA) approval for the treatment of non-metastatic, castration-resistant prostate cancer (nmCRPC) in only five months, Heather Leach, PhD, Healthcare Director at GlobalData, a leading data and analytics company, offers her view on the impact of Nubeqa on the prostate […]
Read more

Indian’s big pharma companies finding new growth opportunities in China, a market set to be worth US$209bn by 2022, says GlobalData

Indian pharmaceutical companies are finding lucrative opportunities for growth in the Chinese pharma market, which is set to rise from nearly US$132bn in 2018 to more than US$209bn by 2022, says GlobalData, a leading data and analytics company. Prashant Khadayate, Pharma Analyst at GlobalData, comments: “The Chinese pharma market is the second largest pharma market […]
Read more

Global B-cell NHL market set to reach $9.2bn by 2027

The B-cell non-Hodgkin’s lymphoma (NHL) market is expected to grow from $5.7bn in 2017 to $9.2bn by 2027 across the seven major markets (7MM*) at a compound annual growth rate (CAGR) of 4.9%, according to GlobalData, a leading data and analytics company. The company’s latest report: ‘B-Cell Non-Hodgkin’s Lymphoma (NHL): Opportunity Analysis and Forecasts to […]
Read more

Global post-traumatic stress disorder market set to reach US$1.2bn by 2028

The total post-traumatic stress disorder market was estimated to be worth US$211.4m across the seven major markets (7MM*) in 2018. This is expected to grow at a compound annual growth rate (CAGR) of 18.7% to reach US$1.2bn by 2028, according to GlobalData, a leading data and analytics company. GlobalData’s latest report: ‘Post-Traumatic Stress Disorder (PTSD): […]
Read more

Global spinal muscular atrophy market set to reach US$6.6bn in 2028

The total spinal muscular atrophy (SMA) market was estimated to be worth US$1.5bn across the seven major markets (7MM*) in 2018. This is expected to grow to US$6.6bn in 2028, at an impressive compound annual growth rate (CAGR) of 16%, according to GlobalData, a leading data and analytics company. GlobalData’s latest report: ‘Spinal Muscular Atrophy […]
Read more
1 … 105 106 107 108 109 110